NeuroSense Therapeutics Ltd.
General ticker "NRSN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $27.8M (TTM average)
NeuroSense Therapeutics Ltd. does not follow the US Stock Market performance with the rate: -16.6%.
Estimated limits based on current volatility of 2.9%: low 0.69$, high 0.73$
Factors to consider:
- Total employees count: 11 as of 2021
- Price in estimated range
- Earnings for 12 months up through Q4 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [0.76$, 2.24$]
- 2025-12-31 to 2026-12-31 estimated range: [0.67$, 1.97$]
Short-term NRSN quotes
Long-term NRSN plot with estimates
Financial data
| YTD | 2024-12-31 | 2025-12-31 |
|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM |
| Operating Expenses | $9.90MM | $11.09MM |
| Operating Income | $-9.90MM | $-11.09MM |
| Non-Operating Income | $-0.31MM | $-0.04MM |
| Interest Expense | $0.31MM | $0.00MM |
| R&D Expense | $5.70MM | $6.23MM |
| Income(Loss) | $-10.21MM | $-11.12MM |
| Profit(Loss)* | $-10.21MM | $-11.12MM |
| Stockholders Equity | $2.58MM | $-1.56MM |
| Assets | $4.58MM | $1.03MM |
| Operating Cash Flow | $-10.13MM | $-7.67MM |
| Capital expenditure | $0.00MM | $0.01MM |
| Investing Cash Flow | $0.00MM | $-0.01MM |
| Financing Cash Flow | $10.91MM | $4.43MM |
| Earnings Per Share** | $-0.55 | $-0.44 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.